IVH reduces the survival of premature infants significantly and enhances the risk of a number of serious neurologic sequelae. There is no current therapy for IVH.
Based on the disease mechanisms that are shared by HIE and IVH, HIEstem is now being developed for IVH. HIEstem is a second-generation cell therapeutics whose therapeutic effects are potentiated by Thrombin pre-conditioning (patent-technology of Medinno Inc.) Project code of HIEstem for IVH is MS2001.
from Wharton’s Jelly of Umbilical Cord
Wharton’s Jelly-derived Mesenchymal Stem Cells
Enhancing Therapeutic Effects of Wharton's Jelly-derived Mesenchymal Stem Cells
Thrombin pre-conditioned Wharton’s Jelly-derived Mesenchymal Stem Cells (HIEstem)